The effect of a multispecies probiotic on microbiota composition in a clinical trial of patients with diarrhea-predominant irritable bowel syndrome

Neurogastroenterology and Motility

Volumn 30, Issue 12, 2018, Pages

  Hod, Keren ^a,b   Dekel, Roy ^a   Aviv Cohen, Nathaniel ^a   Sperber, Ami ^c   Ron, Yishai ^a   Boaz, Mona ^d   Berliner, Shlomo ^a   Maharshak, Nitsan ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b ASSUTA MEDICAL CENTER   (Israel)

^c BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^d ARIEL UNIVERSITY   (Israel)

Author keywords

diarrhea; gastrointestinal microbiome; irritable bowel syndrome; probiotics

Indexed keywords

BIO 25; BIO 25LR; C REACTIVE PROTEIN; CALGRANULIN; PLACEBO; PROBIOTIC AGENT; RNA 16S; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BIFIDOBACTERIUM; BILOPHILA; BLOATING; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; ENTEROBACTER; FAECALIBACTERIUM; FECES ANALYSIS; FEMALE; FIRMICUTES; HAEMOPHILUS; HUMAN; INFLAMMATORY BOWEL DISEASE; INTESTINE FLORA; IRRITABLE COLON; LACTOBACILLUS; LACTOBACILLUS ACIDOPHILUS; LEUCONOSTOC; MICROBIAL DIVERSITY; MICROBIOME; NONHUMAN; ODORIBACTER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RNA SEQUENCE; RUMINOCOCCUS; STREPTOCOCCUS; VISUAL ANALOG SCALE; COMPLICATION; MICROBIOLOGY;

ADULT; DIARRHEA; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IRRITABLE BOWEL SYNDROME; PROBIOTICS;

EID: 85052455572     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/nmo.13456     Document Type: Article

References (35)

1. Ringel Y. The gut microbiome in irritable bowel syndrome and other functional bowel disorders. Gastroenterol Clin North Am. 2017;46:91-101
2. Schwille-Kiuntke J, Enck P, Zendler C, et al. Postinfectious irritable bowel syndrome: follow-up of a patient cohort of confirmed cases of bacterial infection with Salmonella or Campylobacter. Neurogastroenterol Motil. 2011;23:e479–e488
3. Ianiro G, Tilg H, Gasbarrini A. Antibiotics as deep modulators of gut microbiota: between good and evil. Gut. 2016;65:1906-1915
4. Ford AC, Spiegel BM, Talley NJ, Moayyedi P. Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2009;7:1279-1286
5. Liu HN, Wu H, Chen YZ, Chen YJ, Shen XZ, Liu TT. Altered molecular signature of intestinal microbiota in irritable bowel syndrome patients compared with healthy controls: a systematic review and meta-analysis. Dig Liver Dis. 2017;49:331-337
6. Ringel Y, Carroll IM. Alterations in the intestinal microbiota and functional bowel symptoms. Gastrointest Endosc Clin N Am. 2009;19:141-150, vii
7. Jeffery IB, O'Toole PW, Ohman L, et al. An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut. 2011;61:997-1006
8. Tap J, Derrien M, Tornblom H, et al. Identification of an intestinal microbiota signature associated with severity of irritable bowel syndrome. Gastroenterology. 2017;152:111-123 e8
9. Rajilic-Stojanovic M, Biagi E, Heilig HG, et al. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology. 2011;141:1792-1801
10. Raskov H, Burcharth J, Pommergaard HC, Rosenberg J. Irritable bowel syndrome, the microbiota and the gut-brain axis. Gut Microbes. 2016;7:365-383
11. Konturek PC, Zopf Y. Therapeutic modulation of intestinal microbiota in irritable bowel syndrome. From probiotics to fecal microbiota therapy. MMW Fortschr Med. 2017;159:1-5
12. Hod K, Sperber AD, Ron Y, et al. A double-blind, placebo-controlled study to assess the effect of a probiotic mixture on symptoms and inflammatory markers in women with diarrhea-predominant IBS. Neurogastroenterol Motil. 2017;29:e13037
13. CfDEaR (CDER). Guidance for Industry Irritable Bowel Syndrome — Clinical Evaluation of Products for Treatment. U.S. Department of Health and Human Services. Food and Drug Administration, 2010. https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm. Accessed February 2012
14. O'Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology. 2005;128:541-551
15. Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem. 1999;45:2136-2141
16. Dhaliwal A, Zeino Z, Tomkins C, et al. Utility of faecal calprotectin in inflammatory bowel disease (IBD): what cut-offs should we apply? Frontline Gastroenterol. 2015;6:14-19
17. Bishehsari F, Saadalla A, Khazaie K, et al. Light/dark shifting promotes alcohol-induced colon carcinogenesis: possible role of intestinal inflammatory milieu and microbiota. Int J Mol Sci. 2016;17: http://doi.org/10.3390/ijms17122017
18. Tremblay J, Singh K, Fern A, et al. Primer and platform effects on 16S rRNA tag sequencing. Front Microbiol. 2015;6:771
19. Bybee SM, Bracken-Grissom H, Haynes BD, et al. Targeted amplicon sequencing (TAS): a scalable next-gen approach to multilocus, multitaxa phylogenetics. Genome Biol Evol. 2011;3:1312-1323
20. Zhang J, Kobert K, Flouri T, Stamatakis A. PEAR: a fast and accurate Illumina Paired-End reAd mergeR. Bioinformatics. 2014;30:614-620
21. Caporaso JG, Kuczynski J, Stombaugh J, et al. QIIME allows analysis of high-throughput community sequencing data. Nat Methods. 2010;7:335-336
22. Edgar RC. Search and clustering orders of magnitude faster than BLAST. Bioinformatics. 2010;26:2460-2461
23. Carroll IM, Ringel-Kulka T, Siddle JP, Klaenhammer TR, Ringel Y. Characterization of the fecal microbiota using high-throughput sequencing reveals a stable microbial community during storage. PLoS One. 2012;7:e46953
24. Li K, Bihan M, Yooseph S, Methé BA. Analyses of the microbial diversity across the human microbiome. PLoS One. 2012;7:e32118
25. Segata N, Izard J, Waldron L, et al. Metagenomic biomarker discovery and explanation. Genome Biol. 2011;12:R60
26. Kajander K, Hatakka K, Poussa T, Färkkilä M, Korpela R. A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. Aliment Pharmacol Ther. 2005;22:387-394
27. Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. Cell. 2014;157:121-141
28. Chen J, Chia N, Kalari KR, et al. Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls. Sci Rep. 2016;6:28484
29. Kasai C, Sugimoto K, Moritani I, et al. Comparison of human gut microbiota in control subjects and patients with colorectal carcinoma in adenoma: terminal restriction fragment length polymorphism and next-generation sequencing analyses. Oncol Rep. 2016;35:325-333
30. Marchesi JR, Dutilh BE, Hall N, et al. Towards the human colorectal cancer microbiome. PLoS One. 2011;6:e20447
31. Miquel S, Martin R, Rossi O, et al. Faecalibacterium prausnitzii and human intestinal health. Curr Opin Microbiol. 2013;16:255-261
32. Hardham JM, King KW, Dreier K, et al. Transfer of Bacteroides splanchnicus to Odoribacter gen. nov. as Odoribacter splanchnicus comb. nov., and description of Odoribacter denticanis sp. nov., isolated from the crevicular spaces of canine periodontitis patients. Int J Syst Evol Microbiol. 2008;58:103-109
33. Irvine EJ, Whitehead WE, Chey WD, et al.; Design of Treatment Trials Committee. Design of treatment trials for functional gastrointestinal disorders. Gastroenterology. 2006;130:1538-1551
34. Jellema P, van der Windt DA, Schellevis FG, van der Horst HE. Systematic review: accuracy of symptom-based criteria for diagnosis of irritable bowel syndrome in primary care. Aliment Pharmacol Ther. 2009;30:695-706
35. Corsetti M, Whorwell PJ. Managing irritable bowel syndrome in primary care. Practitioner. 2015;259:21-24, 2–3